Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma : secondary analysis of the phase 3 ENDEAVOR study

DSpace Repository

Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma : secondary analysis of the phase 3 ENDEAVOR study

Author: Goldschmidt, Hartmut; Moreau, Philippe; Ludwig, Heinz; Niesvizky, Ruben; Chng, Wee-Joo; Joshua, Douglas; Weisel, Katja; Spencer, Andrew; Orlowski, Robert Z.; Feng, Shibao; Iskander, Karim S.; Dimopoulos, Meletios A.
Tübinger Autor(en):
Weisel, Katja
Published in: Leukemia & Lymphoma (2018), Bd. 59, H. 6, S. 1364-1374
Verlagsangabe: Taylor & Francis Ltd
Language: English
Full text: http://dx.doi.org/10.1080/10428194.2017.1376743
ISSN: 1029-2403
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)